BLU.TO - BELLUS Health Inc.
| Previous Close | 19.69 |
| Open | 19.76 |
| Bid | 19.78 x 0 |
| Ask | 19.82 x 0 |
| Day's Range | 19.76 - 19.88 |
| 52 Week Range | 8.58 - 19.90 |
| Volume | |
| Avg. Volume | 60,333 |
| Market Cap | 2.508B |
| Beta (5Y Monthly) | -0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.54 |
Business WireBELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl
Business WireBELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
LAVAL, Quebec, May 12, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the quarter ended March 31, 2023.
Business WireBELLUS Health Announces Meeting Updates
LAVAL, Quebec, April 26, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0
- Baystreet
BELLUS, GFL, Great-West at 52-Week Highs
BELLUS Health Inc. (T.BLU) hit a new 52-week high of $19.57 Friday. No news stories available today. GFL ...
Motley FoolWhy Shares of Bellus Health Skyrocketed This Week
Shares of Bellus Health (NASDAQ: BLU) jumped 105.1% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The company, which received a $2 billion buyout offer from GSK (formerly known as GlaxoSmithKline) (NYSE: GSK), closed at $7.06 last week and reached a new 52-week high at $14.50 on Tuesday. The attraction for GSK is camlipixant, Bellus' late-stage pipeline candidate to treat adults with refractory chronic cough (RCC).
- Baystreet
Stocks Start out Downward
Equities in Toronto declined at the open on Wednesday as miners and oil companies tracked commodity ...
ZacksBellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.
- Baystreet
Stocks in play: BELLUS Health Inc
Announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, ...
Business WireGSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
LONDON, April 18, 2023--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). The acquisition provides GSK access to camlipixant
- Baystreet
Inflection, BELLUS, Namsys at 52-Week Highs
Inflection Resources (C.AUCU) hit a new 52-week high of 27 cents Tuesday. No news stories available ...
Motley FoolWhy BELLUS Health Stock Is Rocketing Higher Today
What happened Shares of BELLUS Health (NASDAQ: BLU) were up by a whopping 98.9% as of 10:19 a.m. ET Tuesday morning. The big gain came in response to a $2 billion buyout agreement with British pharma giant GSK (NYSE: GSK).
- The Canadian Press
GSK signs deal to buy Canadian drug developer Bellus Health for US$2 billion
TORONTO — GSK plc has announced a deal to buy Canadian drug developer Bellus Health Inc. for US$2 billion. Under the agreement, GSK will pay US$14.75 per Bellus share in cash. Bellus shares closed at US$7.26 on the Nasdaq market on Monday. Bellus is developing a treatment for refractory chronic cough which is defined as a persistent cough for more than eight weeks that does not respond to treatment for an underlying condition or is otherwise unexplained. The acquisition requires approval by a tw
Simply Wall St.BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Baystreet
TSX Finds Strength at Daily Close, Venture Down on Week
Stocks remained volatile in Canada’s biggest market, but fought their way to positive reading Thursday, ...
Business WireBELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation
LAVAL, Quebec, April 05, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release ("ER") formulation of camlipixant in compar
Business WireBELLUS Health Reports Year 2022 Financial Results and Business Highlights
LAVAL, Quebec, March 21, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the year ended December 31, 2022.
The Motley Fool4 Biotech Stocks That Could Break Through the Market
Four TSX biotech stocks could deliver outsized gains in 2023, as they are poised to break through the market soon. The post 4 Biotech Stocks That Could Break Through the Market appeared first on The Motley Fool Canada.
Business WireBELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
LAVAL, Quebec, March 01, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held Ma
Business WireBELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
LAVAL, Quebec, February 08, 2023--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) A
The Motley Fool2022’s Top Small Caps on the TSX: Are They Buys Today?
These top small-caps were some of the few gainers on the TSX in 2022. But are these stocks worth buying in 2023? The post 2022’s Top Small Caps on the TSX: Are They Buys Today? appeared first on The Motley Fool Canada.
The Motley Fool3 Biotech Stocks to Buy Before the Down Market Is Over
Biotech stocks are high-risk, high-reward investments, although three names are buying opportunities in the current down market. The post 3 Biotech Stocks to Buy Before the Down Market Is Over appeared first on The Motley Fool Canada.
- Simply Wall St.
BELLUS Health Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
BELLUS Health ( TSE:BLU ) Third Quarter 2022 Results Key Financial Results Net loss: US$24.7m (loss widened by 8.0...
The Motley Fool2 Biotech Stocks to Buy Before the Down Market Recovers
While not all biotech stocks are trading at a discount, a holistic recovery is likely to push their prices higher. The post 2 Biotech Stocks to Buy Before the Down Market Recovers appeared first on The Motley Fool Canada.
Business WireBELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec, November 14, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitivity indications, today reported its financial and operating results for the third quarter ended September 30, 2022.
Business WireBELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec, November 10, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.